Will Post-Transplantation Cell Therapies for Pediatric Patients Become Standard of Care?

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 3, 2015, Pages 402-411

  Lankester, Arjan C ^a   Locatelli, Franco ^b   Bader, Peter ^c   Rettinger, Eva ^c   Egeler, Maarten ^d   Katewa, Satyendra ^d   Pulsipher, Michael A ^e   Nierkens, Stefan ^f   Schultz, Kirk ^g   Handgretinger, Rupert ^h   Grupp, Stephan A ⁱ   Boelens, Jaap Jan ^f   Bollard, Catherine M ^j  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^c Practice for Child and Adolescent Psychiatry   (Germany)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e UNIVERSITY OF UTAH   (United States)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j GEORGE WASHINGTON UNIVERSITY   (United States)

more..

Author keywords

Adoptive cellular therapy; Chimeric antigen receptor; Pediatrics; Stem cell transplantation

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CELL THERAPY; CHILDHOOD CANCER; CYTOKINE INDUCED KILLER CELL; CYTOTOXIC T LYMPHOCYTE; DONOR LYMPHOCYTE INFUSION; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEALTH CARE QUALITY; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC CELL; HOST; HUMAN; IMMUNE SYSTEM; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; SELF CONCEPT; STEM CELL TRANSPLANTATION; ADOLESCENT; ALLOGRAFT; BIOLOGICAL THERAPY; CHILD; FEMALE; GRAFT REJECTION; GRAFT VERSUS TUMOR EFFECT; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; INFANT; LYMPHOCYTE TRANSFUSION; MALE; PATHOLOGY; PRESCHOOL CHILD; PROCEDURES;

ADOLESCENT; ALLOGRAFTS; CELL- AND TISSUE-BASED THERAPY; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT REJECTION; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LYMPHOCYTE TRANSFUSION; MALE;

EID: 84922894713     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.07.018     Document Type: Review

References (130)

1. Saglio F., Hanley P.J., Bollard C.M. The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care. Cytotherapy 2014, 16:149-159.
2. Heslop H.E., Slobod K.S., Pule M.A., et al. Long-term outcome of EBV-specific T cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010, 115:925-935.
3. Rooney C.M., Smith C.A., Ng C.Y., et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998, 92:1549-1555.
4. Heslop H.E., Ng C.Y., Li C., et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996, 2:551-555.
5. Rooney C.M., Smith C.A., Ng C.Y., et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 1995, 345:9-13.
6. Papadopoulos E.B., Ladanyi M., Emanuel D., et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. NEngl J Med 1994, 330:1185-1191.
7. Heslop H.E., Brenner M.K., Rooney C.M. Donor T cells to treat EBV-associated lymphoma. NEngl J Med 1994, 331:679-680.
8. + lymphomas after allogeneic hematopoietic cell transplantation. Blood 2012, 119:2644-2656.
9. Lucas K.G., Burton R.L., Zimmerman S.E., et al. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 1998, 91:3654-3661.
10. Comoli P., Basso S., Zecca M., et al. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant 2007, 7:1648-1655.
11. Icheva V., Kayser S., Wolff D., et al. Adoptive transfer of Epstein-Barr virus (EBV) nuclear antigen 1-specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem cell transplantation. JClin Oncol 2012, 31:39-48.
12. Moosmann A., Bigalke I., Tischer J., et al. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood 2010, 115:2960-2970.
13. Uhlin M., Okas M., Gertow J., et al. Anovel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation. Cancer Immunol Immunother 2010, 59:473-477.
14. Walter E.A., Greenberg P.D., Gilbert M.J., et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. NEngl J Med 1995, 333:1038-1044.
15. Riddell S.R., Watanabe K.S., Goodrich J.M., et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992, 257:238-241.
16. Cobbold M., Khan N., Pourgheysari B., et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. JExp Med 2005, 202:379-386.
17. Einsele H., Roosnek E., Rufer N., et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002, 99:3916-3922.
18. Feuchtinger T., Opherk K., Bethge W.A., et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 2010, 116:4360-4367.
19. Gerdemann U., Katari U.L., Papadopoulou A., et al. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther 2013, 21:2113-2121.
20. + T-cell lines. JImmunother 2012, 35:621-628.
21. Micklethwaite K., Hansen A., Foster A., et al. Exvivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:707-714.
22. Peggs K.S., Thomson K., Samuel E., et al. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis 2011, 52:49-57.
23. Perruccio K., Tosti A., Burchielli E., et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 2005, 106:4397-4406.
24. Trivedi D., Williams R.Y., O'Reilly R.J., et al. Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy. Blood 2005, 105:2793-2801.
25. Hromas R., Cornetta K., Srour E., et al. Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation. Blood 1994, 84:1689-1690.
26. Feuchtinger T., Matthes-Martin S., Richard C., et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2006, 134:64-76.
27. Gerdemann U., Keirnan J.M., Katari U.L., et al. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther 2012, 20:1622-1632.
28. Leen A.M., Christin A., Myers G.D., et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood 2009, 114:4283-4292.
29. Papadopoulou A., Gerdemann U., Katari U.L., et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med 2014, 6:1-11.
30. Amir A.L., D'Orsogna L.J., Roelen D.L., et al. Allo-HLA reactivity of virus-specific memory T cells is common. Blood 2010, 115:3146-3157.
31. Melenhorst J.J., Leen A.M., Bollard C.M., et al. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood 2010, 116:4700-4702.
32. Hanley P.J., Cruz C.R., Savoldo B., et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 2009, 114:1958-1967.
33. Leen A.M., Bollard C.M., Mendizabal A.M., et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 2013, 121:5113-5123.
34. Bollard C.M., Gottschalk S., Torrano V., et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. JClin Oncol 2014, 32:798-808.
35. Dunn G.P., Old L.J., Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21:137-148.
36. Boon T., van Baren N. Immunosurveillance against cancer and immunotherapy-synergy or antagonism?. NEngl J Med 2003, 348:252-254.
37. de Visser K.E. Spontaneous immune responses to sporadic tumors: tumor-promoting, tumor-protective or both?. Cancer Immunol Immunother 2008, 57:1531-1539.
38. Reid G.S., Shan X., Coughlin C.M., et al. Interferon-gamma-dependent infiltration of human T cells into neuroblastoma tumors invivo. Clin Cancer Res 2009, 15:6602-6608.
39. Berghuis D., Santos S.J., Baelde H.J., et al. Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression. JPathol 2011, 223:347-357.
40. Restifo N.P., Dudley M.E., Rosenberg S.A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012, 12:269-281.
41. Lowdell M.W., Craston R., Samuel D., et al. Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. Br J Haematol 2002, 117:821-827.
42. Montagna D., Maccario R., Locatelli F., et al. Emergence of antitumor cytolytic T cells is associated with maintenance of hematologic remission in children with acute myeloid leukemia. Blood 2006, 108:3843-3850.
43. Barbaric D., Corthals S.L., Jastaniah W.A., et al. Detection of WT1-specific T cells in paediatric acute lymphoblastic leukaemia patients in first remission. Br J Haematol 2008, 141:271-273.
44. Hambach L., Goulmy E. Immunotherapy of cancer through targeting of minor histocompatibility antigens. Curr Opin Immunol 2005, 17:202-210.
45. Bleakley M., Riddell S.R. Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia. Immunol Cell Biol 2011, 89:396-407.
46. Vivier E., Raulet D.H., Moretta A., et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011, 331:44-49.
47. Moretta L., Locatelli F., Pende D., et al. Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood 2011, 117:764-771.
48. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
49. Pende D., Marcenaro S., Falco M., et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 2009, 113:3119-3129.
50. Ruggeri L., Mancusi A., Capanni M., et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007, 110:433-440.
51. Olson J.A., Leveson-Gower D.B., Gill S., et al. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood 2010, 115:4293-4301.
52. Shlomchik W.D., Couzens M.S., Tang C.B., et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999, 285:412-415.
53. Locatelli F., Pende D., Mingari M.C., et al. Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells. Front Immunol 2013, 4:15.
54. + progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study. Bone Marrow Transplant 2010, 45:1038-1046.
55. Stern M., Passweg J.R., Meyer-Monard S., et al. Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers. Bone Marrow Transplant 2013, 48:433-438.
56. Kloess S., Huenecke S., Piechulek D., et al. IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA. Eur J Immunol 2010, 40:3255-3267.
57. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., et al. Successful adoptive transfer and invivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005, 105:3051-3057.
58. Rubnitz J.E., Inaba H., Ribeiro R.C., et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. JClin Oncol 2010, 28:955-959.
59. Brehm C., Huenecke S., Quaiser A., et al. IL-2-stimulated, but not unstimulated, NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II study. PLoS ONE 2011, 6:e27351.
60. Schmidt-Wolf I.G., Negrin R.S., Kiem H.P., et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. JExp Med 1991, 174:139-149.
61. Introna M., Borleri G., Conti E., et al. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica 2007, 92:952-959.
62. Sangiolo D., Mesiano G., Carnevale-Schianca F., et al. Cytokine-induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation. Expert Opin Biol Ther 2009, 9:831-840.
63. Kuci S., Rettinger E., Voss B., et al. Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation. Haematologica 2010, 95:1579-1586.
64. Linn Y.C., Lau S.K., Liu B.H., et al. Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell. Immunology 2009, 126:423-435.
65. Sangiolo D., Martinuzzi E., Todorovic M., et al. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. Int Immunol 2008, 20:841-848.
66. Laport G.G., Sheehan K., Baker J., et al. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011, 17:1679-1687.
67. Linn Y.C., Niam M., Chu S., et al. The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies. Bone Marrow Transplant 2012, 47:957-966.
68. Rettinger E., Bonig H., Wehner S., et al. Feasibility of IL-15-activated cytokine-induced killer cell infusions after haploidentical stem cell transplantation. Bone Marrow Transplant 2013, 48:1141-1143.
69. Bluestone J.A., Tang Q., Sedwick C.E. Tregulatory cells in autoimmune diabetes: past challenges, future prospects. JClin Immunol 2008, 28:677-684.
70. Tang Q., Henriksen K.J., Bi M., et al. Invitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. JExp Med 2004, 199:1455-1465.
71. + T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood 2004, 104:3804-3812.
72. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003, 9:1144-1150.
73. + T regulatory cells suppress naive and memory T cell proliferation and can be expanded invitro without loss of function. JExp Med 2001, 193:1295-1302.
74. + T cells with regulatory properties isolated from peripheral blood. JExp Med 2001, 193:1285-1294.
75. Di Ianni M., Falzetti F., Carotti A., et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011, 117:3921-3928.
76. Brunstein C.G., Miller J.S., Cao Q., et al. Infusion of exvivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011, 117:1061-1070.
77. + regulatory T cells. Blood 2005, 105:4743-4748.
78. + T regulatory cells. Haematologica 2011, 96:1357-1365.
79. + T cells. JAutoimmun 2008, 30:293-302.
80. Sadelain M., Brentjens R., Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov 2013, 3:388-398.
81. Brentjens R.J., Curran K.J. Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen. Hematology Am Soc Hematol Educ Program 2012, 2012:143-151.
82. Jena B., Dotti G., Cooper L.J. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 2010, 116:1035-1044.
83. Lipowska-Bhalla G., Gilham D.E., Hawkins R.E., et al. Targeted immunotherapy of cancer with CAR T cells: achievements and challenges. Cancer Immunol Immunother 2012, 61:953-962.
84. Park J.R., Digiusto D.L., Slovak M., et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007, 15:825-833.
85. Hoyos V., Savoldo B., Quintarelli C., et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 2010, 24:1160-1170.
86. Savoldo B., Ramos C.A., Liu E., et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. JClin Invest 2011, 121:1822-1826.
87. Pule M.A., Savoldo B., Myers G.D., et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008, 14:1264-1270.
88. Rossig C., Bollard C.M., Nuchtern J.G., et al. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood 2002, 99:2009-2016.
89. Barrett D.M., Singh N., Liu X., et al. Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy. Cytotherapy 2014, 16:619-630.
90. Brentjens R.J., Davila M.L., Riviere I., et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013, 5:177ra38.
91. Grupp S.A., Kalos M., Barrett D., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. NEngl J Med 2013, 368:1509-1518.
92. Hackett P.B., Largaespada D.A., Switzer K.C., et al. Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy. Transl Res 2013, 161:265-283.
93. Cruz C.R., Micklethwaite K.P., Savoldo B., et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 2013, 122:2965-2973.
94. Heslop H.E. Safer CARS. Mol Ther 2010, 18:661-662.
95. Lamers C.H., Sleijfer S., Vulto A.G., et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. JClin Oncol 2006, 24:e20-e22.
96. Linette G.P., Stadtmauer E.A., Maus M.V., et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 2013, 122:863-871.
97. Morgan R.A., Yang J.C., Kitano M., et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010, 18:843-851.
98. Grupp S.A., Frey N.V., Aplenc R., et al. Tcells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce significant invivo proliferation, complete responses and long-term persistence without GVHD in children and adults with relapsed, refractory ALL. Blood 2013, 122:67. [abstract].
99. Teachey D.T., Rheingold S.R., Maude S.L., et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 2013, 121:5154-5157.
100. Lee D.W., Shah N.N., Stetler-Stevenson M., et al. Anti-CD19 chimeric antigen receptor (CAR) T cells produce complete responses with acceptable toxicity but without chronic B-cell aplasia in children with relapsed or refractory acute lymphoblastic leukemia (ALL) even after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 2013, 122:68. [abstract].
101. Johnson L.A., Morgan R.A., Dudley M.E., et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009, 114:535-546.
102. Morgan R.A., Dudley M.E., Wunderlich J.R., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314:126-129.
103. Imai C., Iwamoto S., Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005, 106:376-383.
104. Muller T., Uherek C., Maki G., et al. Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK resistance of lymphoma and leukemia cells. Cancer Immunol Immunother 2008, 57:411-423.
105. Esser R., Muller T., Stefes D., et al. NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. JCell Mol Med 2012, 16:569-581.
106. Altvater B., Landmeier S., Pscherer S., et al. 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. Clin Cancer Res 2009, 15:4857-4866.
107. Uherek C., Tonn T., Uherek B., et al. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 2002, 100:1265-1273.
108. Sahm C., Schonfeld K., Wels W.S. Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor. Cancer Immunol Immunother 2012, 61:1451-1461.
109. Tassev D.V., Cheng M., Cheung N.K. Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor. Cancer Gene Ther 2012, 19:84-100.
110. Chang Y.H., Connolly J., Shimasaki N., et al. Achimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res 2013, 73:1777-1786.
111. Fujisaki H., Kakuda H., Shimasaki N., et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009, 69:4010-4017.
112. Imai C., Mihara K., Andreansky M., et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004, 18:676-684.
113. Pizzitola I., Anjos-Afonso F., Rouault-Pierre K., et al. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells invivo. Leukemia 2014, doi:10.1038/leu.2014.62.
114. Ueno H., Schmitt N., Klechevsky E., et al. Harnessing human dendritic cell subsets for medicine. Immunol Rev 2010, 234:199-212.
115. Bendandi M., Rodriguez-Calvillo M., Inoges S., et al. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. Leuk Lymphoma 2006, 47:29-37.
116. Fujii S., Shimizu K., Fujimoto K., et al. Treatment of post-transplanted, relapsed patients with hematological malignancies by infusion of HLA-matched, allogeneic-dendritic cells (DCs) pulsed with irradiated tumor cells and primed T cells. Leuk Lymphoma 2001, 42:357-369.
117. Kitawaki T., Kadowaki N., Kondo T., et al. Potential of dendritic-cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide- and keyhole-limpet-hemocyanin-pulsed, donor-derived dendritic-cell vaccine for acute myeloid leukemia. Am J Hematol 2008, 83:315-317.
118. Levenga H., Schaap N., Maas F., et al. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma. Biol Blood Marrow Transplant 2010, 16:320-332.
119. Grigoleit G.U., Kapp M., Hebart H., et al. Dendritic cell vaccination in allogeneic stem cell recipients: induction of human cytomegalovirus (HCMV)-specific cytotoxic T lymphocyte responses even in patients receiving a transplant from an HCMV-seronegative donor. JInfect Dis 2007, 196:699-704.
120. Geiger J.D., Hutchinson R.J., Hohenkirk L.F., et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001, 61:8513-8519.
121. Eyrich M., Rachor J., Schreiber S.C., et al. Dendritic cell vaccination in pediatric gliomas: lessons learnt and future perspectives. Front Pediatr 2013, 1:12.
122. Friedenstein A.J., Petrakova K.V., Kurolesova A.I., et al. Heterotopic of bone marrow: analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968, 6:230-247.
123. Nauta A.J., Fibbe W.E. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007, 110:3499-3506.
124. Le Blanc K., Rasmusson I., Sundberg B., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
125. Le Blanc K., Frassoni F., Ball L., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
126. Lucchini G., Introna M., Dander E., et al. Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Biol Blood Marrow Transplant 2010, 16:1293-1301.
127. Ball L.M., Bernardo M.E., Roelofs H., et al. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. Br J Haematol 2013, 163:501-509.
128. Introna M., Lucchini G., Dander E., et al. Treatment of graft-versus-host disease with mesenchymal stromal cells: a phase i study on 40 adult and pediatric patients. Biol Blood Marrow Transplant 2014, 20:375-381.
129. Prasad V.K., Lucas K.G., Kleiner G.I., et al. Efficacy and safety of exvivo cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant 2011, 17:534-541.
130. Allison M. Genzyme backs Osiris, despite Prochymal flop. Nat Biotechnol 2009, 27:966-967.